| | Studies | Jadad scores | Syndrome differentiation | Sample size | Age (year) | Intervention | Treatment period | Follow-up | Outcome measure | Adverse events | | T | C | T | C | T | C | T | C |
| | Fang 2014 | 4 | Yes | 257 | 257 | 54.95 ± 9.50 | 54.61 ± 10.51 | Shenzhutiaopi granule | LM | 12 m | NR | a, b, c, d, e, f | 9 | 5 | | Grant 2013 | 7 | No | 39 | 32 | 58.3 | 59.9 | Jiangtangxiaozhi capsules | Placebo + LM | 4 m | 2m | c, d, e, f | 1 | 0 | | Huang 2016 | 5 | No | 64 | 63 | 52.02 ± 8.60 | 51.05 ± 9.25 | Tangyiping granules | LM | 3 m | 24 m | a, b, c, d, e, f | 0 | 0 | | Ke 2012 | 4 | Yes | 45 | 40 | 46.5 ± 7.3 | 45.7 ± 7.5 | Lingguizhugan decoction | LM | 6 m | NR | a, b, c, d, e, f | 5 | 0 | | Lian 2014 | 7 | No | 210 | 210 | 52.95 ± 10.06 | 51.86 ± 10.16 | Tianqi capsules | Placebo + LM | 12 m | NR | a, b, f | 15 | 11 | | Shi 2016 | 4 | No | 34 | 31 | 47.1 ± 7.1 | 49.9 ± 7.2 | Jinlida granule | LM | 3 m | NR | a, b, c, d, e, f | 1 | 1 | | Sun 2011 | 4 | No | 110 | 106 | 51.0 ± 9.3 | 51.4 ± 9.5 | Tianqi capsules | Placebo + LM | 12 m | NR | a, b, c, d | NR | NR | | Wang 2017 | 7 | No | 182 | 180 | 55.49 ± 8.61 | 53.49 ± 8.85 | Jinqijiangtang tablet | placebo + LM | 12 m | 12 m | a, b, f | 3 | 5 | | Wang 2018 | 4 | Yes | 70 | 70 | 43.7 ± 5.8 | 42.9 ± 6.1 | Tangqianping granule | Metformin + LM | 3 m | NR | a, b, c, e, f | 1 | 0 | | Wei 2008 | 4 | Yes | 70 | 70 | 51.3 ± 8.8 | 50.7 ± 8.1 | Tang no. 1 granule | LM | 6 m | NR | a, b, c, d, e, f | 0 | 0 | | Zhao 2014 | 5 | Yes | 35 | 35 | 46.49 ± 12.63 | 44.02 ± 12.93 | Xiaotangsevenherb formula | LM | 3 m | NR | c, d, e, f | 0 | 0 |
|
|
